News and Announcements
Kazia announces positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma
- Published December 03, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Our Chief Executive Officer, Dr James Garner, recently sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.
The interview covers:
- How the data shows a progression free survival in the eight patients treated of around 8.4 months, which compares very favourably to benchmarks for glioblastoma
- How GDC-0084 extended progression free survival of MGMT methylated patients who are resistant to temozolomide, the current standard of care
- How Kazia believes GDC-0084 has every possibility of being the next drug that is FDA approved for glioblastoma
- The $US1.5 billion untapped market opportunity in glioblastoma
- That Kazia is looking to use GDC-0084 in other forms of brain cancer
Watch the video interview here.
Interview with BioWorld
In addition, Dr Garner was also interviewed in BioWorld on the interim efficacy data as well as the overall GDC-0084 program.
In the interview, Dr Garner said that by the standards of drug development, the GDC-0084 program “has moved incredibly fast.”
“In one sense, that’s exactly how it should be for a drug with as terrible a prognosis as glioblastoma,” he added. “But it also reflects what we’ve tried to do in Kazia. Our goal has been to put forward this agile model for drug development, and the GDC-0084 story is a good illustration of exactly what we’ve been trying to do as a company.”
About KaziaTherapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
